ES2534634T3 - Ácidos 2-aril-propiónicos y derivados y composiciones farmacéuticas que los contienen - Google Patents
Ácidos 2-aril-propiónicos y derivados y composiciones farmacéuticas que los contienen Download PDFInfo
- Publication number
- ES2534634T3 ES2534634T3 ES09783167.1T ES09783167T ES2534634T3 ES 2534634 T3 ES2534634 T3 ES 2534634T3 ES 09783167 T ES09783167 T ES 09783167T ES 2534634 T3 ES2534634 T3 ES 2534634T3
- Authority
- ES
- Spain
- Prior art keywords
- amino
- phenyl
- linear
- alkyl
- branched
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000001188 haloalkyl group Chemical group 0.000 abstract 2
- -1 hydroxy, carboxyl Chemical group 0.000 abstract 2
- VPSJWRREMDJLPT-SECBINFHSA-N (2r)-2-[4-[(4-methyl-1,3-oxazol-2-yl)amino]phenyl]propanoic acid Chemical compound C1=CC([C@H](C(O)=O)C)=CC=C1NC1=NC(C)=CO1 VPSJWRREMDJLPT-SECBINFHSA-N 0.000 abstract 1
- FDCNKYFUHVZCSP-SECBINFHSA-N (2r)-2-[4-[(4-methyl-1,3-thiazol-2-yl)amino]phenyl]propanoic acid Chemical compound C1=CC([C@H](C(O)=O)C)=CC=C1NC1=NC(C)=CS1 FDCNKYFUHVZCSP-SECBINFHSA-N 0.000 abstract 1
- PEWMCDTVGCALBX-SNVBAGLBSA-N (2r)-2-[4-[(4-tert-butyl-1,3-thiazol-2-yl)amino]phenyl]propanoic acid Chemical compound C1=CC([C@H](C(O)=O)C)=CC=C1NC1=NC(C(C)(C)C)=CS1 PEWMCDTVGCALBX-SNVBAGLBSA-N 0.000 abstract 1
- LPPNMWHZIUTUIZ-SSDOTTSWSA-N (2r)-2-[4-[[4-(trifluoromethyl)-1,3-oxazol-2-yl]amino]phenyl]propanoic acid Chemical compound C1=CC([C@H](C(O)=O)C)=CC=C1NC1=NC(C(F)(F)F)=CO1 LPPNMWHZIUTUIZ-SSDOTTSWSA-N 0.000 abstract 1
- OUGCUPYREMACGK-SSDOTTSWSA-N (2r)-2-[4-[[4-(trifluoromethyl)-1,3-thiazol-2-yl]amino]phenyl]propanoic acid Chemical compound C1=CC([C@H](C(O)=O)C)=CC=C1NC1=NC(C(F)(F)F)=CS1 OUGCUPYREMACGK-SSDOTTSWSA-N 0.000 abstract 1
- 125000006677 (C1-C3) haloalkoxy group Chemical group 0.000 abstract 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 1
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 abstract 1
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 abstract 1
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 abstract 1
- 125000006729 (C2-C5) alkenyl group Chemical group 0.000 abstract 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 1
- 101100294106 Caenorhabditis elegans nhr-3 gene Proteins 0.000 abstract 1
- 125000004442 acylamino group Chemical group 0.000 abstract 1
- 125000004423 acyloxy group Chemical group 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 abstract 1
- 125000003884 phenylalkyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/48—Nitrogen atoms not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08164605 | 2008-09-18 | ||
| EP08164605A EP2166006A1 (en) | 2008-09-18 | 2008-09-18 | 2-aryl-propionic acids and derivatives and pharmaceutical compositions containing them |
| PCT/EP2009/062109 WO2010031835A2 (en) | 2008-09-18 | 2009-09-18 | 2-aryl-propionic acids and derivatives and pharmaceutical compositions containing them |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2534634T3 true ES2534634T3 (es) | 2015-04-27 |
Family
ID=40291117
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES09783167.1T Active ES2534634T3 (es) | 2008-09-18 | 2009-09-18 | Ácidos 2-aril-propiónicos y derivados y composiciones farmacéuticas que los contienen |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US8624036B2 (enExample) |
| EP (2) | EP2166006A1 (enExample) |
| JP (1) | JP5571669B2 (enExample) |
| CN (1) | CN102159558B (enExample) |
| AU (1) | AU2009294558B2 (enExample) |
| CA (1) | CA2737099C (enExample) |
| CY (1) | CY1116176T1 (enExample) |
| DK (1) | DK2346841T3 (enExample) |
| ES (1) | ES2534634T3 (enExample) |
| HR (1) | HRP20150395T1 (enExample) |
| IL (1) | IL211683A (enExample) |
| PL (1) | PL2346841T3 (enExample) |
| PT (1) | PT2346841E (enExample) |
| RU (1) | RU2520212C2 (enExample) |
| SI (1) | SI2346841T1 (enExample) |
| SM (1) | SMT201500098B (enExample) |
| WO (1) | WO2010031835A2 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2634185T3 (pl) | 2012-03-02 | 2016-06-30 | Sareum Ltd | Inhibitory kinazy TYK2 |
| US10046002B2 (en) | 2013-08-02 | 2018-08-14 | Syntrix Biosystems Inc. | Method for treating cancer using chemokine antagonists |
| US10561676B2 (en) * | 2013-08-02 | 2020-02-18 | Syntrix Biosystems Inc. | Method for treating cancer using dual antagonists of CXCR1 and CXCR2 |
| KR102191084B1 (ko) * | 2013-09-03 | 2020-12-15 | 사름 리미티드 | 약제학적 화합물 |
| AR103399A1 (es) * | 2015-01-15 | 2017-05-10 | Actelion Pharmaceuticals Ltd | Derivados de (r)-2-metil-piperazina como moduladores del receptor cxcr3 |
| EP3117835A1 (en) * | 2015-07-14 | 2017-01-18 | Dompé farmaceutici s.p.a. | Il-8 inhibitors for use in the treatment of certain urological disorders |
| SG11201804484YA (en) | 2016-01-15 | 2018-07-30 | Dompe Farm Spa | Il-8 inhibitors for use in the treatment of chemotherapy-induced peripheral neuropathy |
| EP3192504A1 (en) | 2016-01-15 | 2017-07-19 | Dompé farmaceutici S.p.A. | Il-8 inhibitors for use in the treatment of chemotherapy-induced peripheral neuropathy |
| US11291641B2 (en) | 2016-10-03 | 2022-04-05 | The Children's Medical Center Corporation | Prevention and treatment of diabetic nephropathy |
| GB201617871D0 (en) | 2016-10-21 | 2016-12-07 | Sareum Limited | Pharmaceutical compounds |
| US10660909B2 (en) | 2016-11-17 | 2020-05-26 | Syntrix Biosystems Inc. | Method for treating cancer using chemokine antagonists |
| EP3342407A1 (en) * | 2017-01-03 | 2018-07-04 | Dompé farmaceutici S.p.A. | Il-8 inihibitors for use in the treatment of some urological disorders |
| EP3409277A1 (en) * | 2017-05-30 | 2018-12-05 | Dompé farmaceutici s.p.a. | Il-8 inhibitors for use in the treatment and/or prevention of bacterial secondary infections |
| EP3476390A1 (en) | 2017-10-24 | 2019-05-01 | Dompé farmaceutici S.p.A. | Il-8 inhibitors for use in the treatment of sarcomas |
| WO2019165315A1 (en) | 2018-02-23 | 2019-08-29 | Syntrix Biosystems Inc. | Method for treating cancer using chemokine antagonists alone or in combination |
| GB201816369D0 (en) | 2018-10-08 | 2018-11-28 | Sareum Ltd | Pharmaceutical compounds |
| EP3868369A1 (en) | 2020-02-21 | 2021-08-25 | Dompe' Farmaceutici S.P.A. | Cxcl8 inhibitor and pharmaceutical composition thereof for use in the treatment of cancer-related fatigue |
| EP3868368A1 (en) | 2020-02-21 | 2021-08-25 | Dompe' Farmaceutici S.P.A. | Cxcl8 (interleukin-8) activity inhibitor and corticosteroid combination and pharmaceutical composition and use thereof |
| EP3884932A1 (en) | 2020-03-26 | 2021-09-29 | Dompe' Farmaceutici S.P.A. | Cxcl8 inhibitors for use in the treatment of covid-19 |
| CN115397404A (zh) | 2020-03-26 | 2022-11-25 | 东佩制药股份公司 | 用于治疗covid-19的cxcl8抑制剂 |
| EP4008325A1 (en) | 2020-12-02 | 2022-06-08 | Dompe' Farmaceutici S.P.A. | Cxcl8 inhibitors for use in the treatment of covid-19 |
| EP3907214A1 (en) * | 2020-05-04 | 2021-11-10 | Dompe' Farmaceutici S.P.A. | Co-crystal of ketoprofen, lysine and gabapentin, pharmaceutical compositions and their medical use |
| WO2022098822A1 (en) | 2020-11-05 | 2022-05-12 | Icahn School Of Medicine At Mount Sinai | Cxcr1/cxcr2 inhibitors for use in treating myelofibrosis |
| EP4052702A1 (en) | 2021-03-04 | 2022-09-07 | Dompé farmaceutici S.p.a. | Cxcl8 inhibitor and pharmaceutical composition thereof for use in the treatment of seizures |
| EP4397305A1 (en) | 2023-01-05 | 2024-07-10 | Dompe' Farmaceutici S.P.A. | Cxcl8 inhibitors for use in the treatment of ocular mucous membrane pemphigoid and/or oral mucous membrane pemphigoid |
| EP4406942A1 (en) * | 2023-01-26 | 2024-07-31 | Dompe' Farmaceutici S.P.A. | Stable monohydrate of df2755a and process for its preparation |
| EP4563594A1 (en) | 2023-11-28 | 2025-06-04 | Dompe' Farmaceutici SpA | Cxcl8 inhibitors for use in the treatment of tumors with low stromal cav1 levels |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1051906A (en) * | 1973-10-24 | 1979-04-03 | Shionogi And Co. | Thiazole derivatives and production thereof |
| JPS5537556B2 (enExample) * | 1973-12-27 | 1980-09-29 | ||
| US4025528A (en) * | 1973-10-24 | 1977-05-24 | Shionogi & Co., Ltd. | Thiazole derivatives of benzoic and phenylalkanoic acids |
| JPS565747B2 (enExample) * | 1973-10-24 | 1981-02-06 | ||
| JPS5629871B2 (enExample) * | 1974-05-22 | 1981-07-10 | ||
| JPS62142168A (ja) * | 1985-10-16 | 1987-06-25 | Mitsubishi Chem Ind Ltd | チアゾ−ル誘導体及びそれを有効成分とするロイコトリエンきつ抗剤 |
| IT1298214B1 (it) | 1998-01-28 | 1999-12-20 | Dompe Spa | Sali dell'acido (r) 2-(3-benzoilfenil) propionico e loro composizioni farmaceutiche. |
| IT1303249B1 (it) * | 1998-10-23 | 2000-11-06 | Dompe Spa | Alcune n-(2-aril-propionil)-solfonammidi e preparazionifarmaceutiche che le contengono. |
| IT1317826B1 (it) | 2000-02-11 | 2003-07-15 | Dompe Spa | Ammidi, utili nell'inibizione della chemiotassi dei neutrofiliindotta da il-8. |
| ITMI20012434A1 (it) | 2001-11-20 | 2003-05-20 | Dompe Spa | Acidi 2-aril-propionici e composizioni farmaceutiche che li contengono |
| WO2003062215A1 (en) * | 2002-01-25 | 2003-07-31 | Kylix Pharmaceuticals B.V. | 4(hetero-) aryl substituted (thia-/oxa-/pyra) zoles for inhibition of tie-2 |
| DE602005016937D1 (de) * | 2004-03-23 | 2009-11-12 | Dompe Pha R Ma Spa Res & Mfg | Pharmazeutische zusammensetzung |
| HRP20161260T1 (hr) * | 2005-11-24 | 2016-11-18 | Dompé Farmaceutici S.P.A. | Derivati (r)-arilkilamina i farmaceutski pripravci koji ih sadrže |
| AU2007253424B2 (en) * | 2006-05-18 | 2013-03-07 | Dompe' Farmaceutici S.P.A. | (2R)-2-[(4-sulfonyl)aminophenyl]propanamides and pharmaceutical compositions containing them |
| ES2394641T3 (es) * | 2006-12-19 | 2013-02-04 | Dompe' S.P.A. | Ácidos 2-aril-2-fluoropropanoicos y derivados y composiciones farmacéuticas que los contienen |
| DE602008005488D1 (de) * | 2007-10-18 | 2011-04-21 | Dompe Spa | (r)-4-(heteroaryl)phenylethylderivate und pharmazeutische zusammensetzungen damit |
-
2008
- 2008-09-18 EP EP08164605A patent/EP2166006A1/en not_active Withdrawn
-
2009
- 2009-09-18 US US13/063,105 patent/US8624036B2/en active Active
- 2009-09-18 PL PL09783167T patent/PL2346841T3/pl unknown
- 2009-09-18 DK DK09783167.1T patent/DK2346841T3/en active
- 2009-09-18 WO PCT/EP2009/062109 patent/WO2010031835A2/en not_active Ceased
- 2009-09-18 CN CN200980136860.5A patent/CN102159558B/zh active Active
- 2009-09-18 PT PT97831671T patent/PT2346841E/pt unknown
- 2009-09-18 HR HRP20150395TT patent/HRP20150395T1/hr unknown
- 2009-09-18 AU AU2009294558A patent/AU2009294558B2/en active Active
- 2009-09-18 RU RU2011114992/04A patent/RU2520212C2/ru active
- 2009-09-18 SI SI200931170T patent/SI2346841T1/sl unknown
- 2009-09-18 ES ES09783167.1T patent/ES2534634T3/es active Active
- 2009-09-18 CA CA2737099A patent/CA2737099C/en active Active
- 2009-09-18 JP JP2011527334A patent/JP5571669B2/ja active Active
- 2009-09-18 EP EP09783167.1A patent/EP2346841B1/en active Active
-
2011
- 2011-03-10 IL IL211683A patent/IL211683A/en active IP Right Grant
-
2015
- 2015-04-08 CY CY20151100336T patent/CY1116176T1/el unknown
- 2015-04-22 SM SM201500098T patent/SMT201500098B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0918759A2 (pt) | 2015-12-29 |
| EP2346841A2 (en) | 2011-07-27 |
| SMT201500098B (it) | 2015-07-09 |
| CN102159558B (zh) | 2015-01-07 |
| RU2520212C2 (ru) | 2014-06-20 |
| CA2737099A1 (en) | 2010-03-25 |
| EP2346841B1 (en) | 2015-01-14 |
| EP2166006A1 (en) | 2010-03-24 |
| WO2010031835A2 (en) | 2010-03-25 |
| AU2009294558A1 (en) | 2010-03-25 |
| JP5571669B2 (ja) | 2014-08-13 |
| CA2737099C (en) | 2016-07-05 |
| CN102159558A (zh) | 2011-08-17 |
| PT2346841E (pt) | 2015-05-07 |
| US20110207785A1 (en) | 2011-08-25 |
| JP2012502957A (ja) | 2012-02-02 |
| IL211683A0 (en) | 2011-06-30 |
| AU2009294558B2 (en) | 2014-12-18 |
| PL2346841T3 (pl) | 2015-07-31 |
| SI2346841T1 (sl) | 2015-07-31 |
| DK2346841T3 (en) | 2015-04-20 |
| IL211683A (en) | 2014-01-30 |
| CY1116176T1 (el) | 2017-02-08 |
| RU2011114992A (ru) | 2012-10-27 |
| WO2010031835A3 (en) | 2010-06-24 |
| HRP20150395T1 (hr) | 2015-06-19 |
| US8624036B2 (en) | 2014-01-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2534634T3 (es) | Ácidos 2-aril-propiónicos y derivados y composiciones farmacéuticas que los contienen | |
| ES2618630T3 (es) | Composiciones terapéuticas y métodos de uso relacionados | |
| PE20040087A1 (es) | 2-(2,6-diclorofenil)-diarilimidazoles | |
| JP2017526636A5 (enExample) | ||
| RU2397168C2 (ru) | Производные тиофена в качестве ингибиторов снк 1 | |
| PE20020693A1 (es) | Agonistas del receptor alfa activado del proliferador de peroxisomas | |
| JP2012502957A5 (enExample) | ||
| AR059895A1 (es) | Derivados biciclicos de acidos carboxilicos que resultan de utilidad para tratar trastornos metabolicos | |
| AR047085A1 (es) | Derivados de (3-oxo-3,4-dihidro-quinoxalina-2-il-amino)benzamida y compuestos relacionados como inhibidores de glucogeno fosforilasa para el tratamiento de diabetes y obesidad | |
| ECSP10010405A (es) | Procesos e intermediarios para la preparacion de derivados de acido 5-bifenil-4-il-2-metilpentanoico | |
| PE20010489A1 (es) | Nueva forma cristalina de la sal disodica del acido n-[4-[2-[2-amino-4,7-dihidro-4-oxo-3h-pirrolo[2,3-d]-pirimidin-5-il)etil]benzoil]-l-glutamico y procedimientos para el mismo | |
| AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
| ES2578302T3 (es) | Compuestos de 5,6-dihidro-1H-piridin-2-ona | |
| AR045510A1 (es) | Derivados de 1,3 diazoles | |
| RU2008135153A (ru) | Применение нитрооксипроизводного лекарственного средства для лечения мышечной дистрофии | |
| AR044152A1 (es) | Derivados de alquilarilo, metodo de preparacion y uso para el tratamiento de la obesidad | |
| CL2012000999A1 (es) | Compuestos derivados de pirazoloespirocetona sustituida, inhibidores de acetil-coa carboxilasa; composicion farmaceutica que los comprende; uso para tratar o retrasar la progresion o el inicio de diabetes tipo 2, higado graso no alcoholico (hgna) o la resistencia hepatica a la insulina. | |
| ES2546198T3 (es) | Tratamiento contra la glomerulonefritis | |
| ES2655091T3 (es) | Derivados del ácido pirrolidíncarboxílico como agonistas del receptor 43 acoplado a proteína G (GPR43), composición farmacéutica y métodos para su uso en el tratamiento de trastornos metabólicos | |
| CU23706B7 (es) | Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparación y las composiciones farmacéuticas que las contienen | |
| AR083017A1 (es) | Prodrogas de ester de [3-(1-(1h-imidazol-4-il)etil)-2-metilfenil]metanol | |
| AR064116A1 (es) | Sal de potasio cristalina de analogos de lipoxina a4 | |
| AR060568A1 (es) | Acidos bifenilcarboxilicos substituidos y sus derivados | |
| RU2008149936A (ru) | (2r)-2-[(4-сульфонил)аминофенил]пропанамиды и содержащие их фармацевтические композиции | |
| PE20221630A1 (es) | Derivado de amino arilo novedoso util como inhibidor de diacilglicerol aciltransferasa 2 y uso del mismo |